The Brand Name MODUS Has Generic Salt :: Medroxyprogesterone 

MODUS  Is From Company Gsk Priced :: Rs. 49.49

MODUS have Medroxyprogesterone is comes under Sub class Contraceptive Drugs of  Main Class Reproductive System

Main Medicine Class:: Reproductive System  Sub Medicine Class :: Contraceptive Drugs 

Indications for Drugs ::

Menorrhagia, endometriosis, menopausal HRT, breast cancer, endometrial and renal carcinoma, prostatic carcinoma, secondary amenorrhoea, contraception, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer, to reduce the incidence of endometrial hyperplasia in non-hysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets

Drug Dose ::

Adult: PO Menorrhagia 2.5-10 mg/day for 5-10 days on days 16-21 of the menstrual cycle. Repeat for 2 cycles. Mild to moderate endometriosis 10 mg 3 times/day for 90 consecutive days, beginning on the first day of the menstrual cycle. As progestogen component in menopausal HRT Dosage depends on oestrogen component of therapy, several regimens are used: 1.5 mg, 2.5 mg or 5 mg/day; 5 or 10 mg/day for 12-14 days of a 28-day cycle; 20 mg/day for 14 days of a 91-day cycle. Abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology: Beginning on the calculated 16th or 21st day of the menstrual cycle, 5 or 10 mg of Medroxyprogesterone acetate may be given daily for 5 to 10 days. Reduction of endometrial hyperplasia in postmenopausal women receiving daily 0.625 mg conjugated estrogens : Medroxyprogesterone acetate tablets may be given in dosages of 5 or 10 mg daily for 12 to 14 consecutive days per month, in postmenopausal women receiving daily 0.625 mg conjugated estrogens, either beginning on the 1st day of the cycle or the 16th day of the cycle. Breast cancer 0.4-1.5 g/day. Max: 2 g/day. Palliation of endometrial and renal carcinoma 200-600 mg/day. Palliation of prostatic carcinoma 100-600 mg/day. Secondary amenorrhoea 5-10 mg/day for 5-10 days. Repeat for 3 cycles.

Contraindication ::

Thromboembolic disorders; cerebral apoplexy; severe hepatic dysfunction; incomplete abortion, hormone-dependent carcinoma; Undiagnosed vaginal bleeding, Undiagnosed urinary tract bleeding, Known or suspected pregnancy, Undiagnosed breast pathology, Missed abortion, Active thromboembolic disorders, Markedly impaired liver function,

Drug Precautions ::

Breakthrough bleeding is likely to occur in patients being treated for endometriosis. May cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, asthma, or cardiac or renal dysfunction, require careful observation. A decrease in glucose tolerance has been observed in some patients. Patients with depression, DM, epilepsy, asthma, migraine, hypertension, renal or cardiac dysfunction. Monitor patient closely for loss of vision, proptosis, diplopia and thromboembolic disorders. Lactation.

Drug Side Effects ::

Depression, fluid retention. Fatigue, insomnia, dizziness, headache, nausea; breast tenderness; wt gain/loss, anorexia; cholestatic jaundice; pain at Inj site. Potentially Fatal: Thrombophlebitis and pulmonary embolism.

Pregnancy category ::

5

Drug Mode of Action ::  

Medroxyprogesterone is a synthetic progestogen which converts the proliferative phase of the endometrium into secretory phase. It has some androgenic and anabolic activities but no oestrogenic effects. Parenteral use leads to inhibition of pituitary gonadotropins, thus preventing follicular maturation and ovulation.

Drug Interactions ::

Aminoglutethimide and enzyme-inducing drugs (e.g. carbamazepine, griseofulvin, phenobarbital, rifampicin, phenytoin) may reduce plasma concentrations leading to reduced efficacy. Additional measures required when medroxyprogesterone is used for contraception during coadministration with these drugs.